Actively Recruiting

Phase 2
Age: 60Years +
All Genders
NCT06867549

Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II

Led by Washington University School of Medicine · Updated on 2025-10-24

70

Participants Needed

1

Research Sites

160 weeks

Total Duration

On this page

Sponsors

W

Washington University School of Medicine

Lead Sponsor

N

National Institute of Mental Health (NIMH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The investigators hypothesize that brief behavioral therapy and targeted propofol infusion in depressed geriatric patients will augment subsequent slow wave sleep and improve clinical and cognitive outcomes. The team will recruit 70 participants for a double-blinded placebo controlled randomized controlled trial. Two propofol infusions, 2-6 days apart, will be administered, targeting either a low propofol dose arm (minimal EEG slow waves, brain effect-site concentration 1-2 mcg/ml) or moderate dose propofol arm (maximal induction of EEG slow waves, brain effect site concentration of \>2.5 mcg/ml). The pharmacologic intervention will be paired with 3-4 sessions of Brief Behavioral Therapy for Insomnia for all participants. To minimize bias, there will be no specific gender or ethnic background consideration for enrollment. This will be a single site investigation at Washington University Medical Center.

CONDITIONS

Official Title

Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II

Who Can Participate

Age: 60Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed and dated informed consent form
  • Willingness to comply with all study procedures and availability for the study duration
  • Age 60 years or older
  • English speaking
  • Diagnosis of depression not responding to at least one adequate trial of oral antidepressants for the current episode
Not Eligible

You will not qualify if you...

  • Presence of symptomatic coronary artery disease
  • Marked congestive heart failure or cardiomyopathy (NYHA Class III or higher, LVEF less than 40%, or greater than mild right ventricular systolic dysfunction)
  • Prior allergic or adverse reaction to propofol
  • Resting heart rate below 50 beats per minute
  • Recent treatment with Electroconvulsive therapy, Transcranial Magnetic Stimulation, or vagal nerve stimulation within 6 weeks
  • Body mass index over 35
  • Active suicidal ideation with some intent (C-SSRS score 4 or greater)
  • Mild or greater dementia (MoCA score below 23)
  • Diagnosis of schizophrenia or bipolar disorder
  • Use of non-prescribed amphetamines, opioids, cocaine, or phencyclidine; urine THC level greater than 150 ng/ml
  • Consumption of more than 14 beers per week or equivalent
  • Anesthetic exposure within the past 4 weeks
  • Concurrent use of benzodiazepines over 2 mg/day lorazepam equivalent, trazodone over 50 mg/day, or gabapentin over 600 mg/day

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Washington University School of Medicine/Barnes-Jewish Hospital

St Louis, Missouri, United States, 63110

Actively Recruiting

Loading map...

Research Team

S

Sarah E Knarr

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here